Purchasing price of Gleevec in India, how much does 120 tablets of Gleevec cost in China, Gleevec 13621079267 in India

Gleevec (imatinib mesylate) is packaged as tablets per bottle, and each tablet contains imatinib mesylate, which is equivalent to imatinib free base. Medicines are packaged in white polyethylene bottles. :../.
_
. The results of the Phase III clinical trial show that Gleevec is more effective in the treatment of newly diagnosed chronic myelogenous leukemia (CML), and some patients can get cytology results. Relief, the effective rate for the acceleration period and the acute change period also reached and 3 respectively. Gleevec is also highly effective against gastrointestinal stromal tumors.
. Indications:
. Gleevec (imatinib mesylate) is used to treat newly diagnosed Philadelphia chromosome-positive (+) adults with chronic myelogenous leukemia in the chronic phase.
. Gleevec (imatinib mesylate) is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase and accelerated phase. Imatinib mesylate is also used to treat patients who have been Interferon-treated chronic myelogenous leukemia in the chronic phase.
. Gleevec (imatinib mesylate) is also used to treat pediatric chronic myelogenous leukemia that has relapsed after myelosuppression or has failed to respond to interferon therapy.
. Gastrointestinal stromal tumor
. Gleevec (imatinib mesylate) is used to treat positive inoperable or metastatic malignant gastrointestinal stromal tumors!
.Main toxic and side effects The most common toxic and side effects include: superficial edema, malignancy and vomiting, muscle aches, muscle cramps, rash and diarrhea.
. Hematologic toxicities, including neutropenia and thrombocytopenia, are common side effects of Gleevec (imatinib) treatment, but they occur less frequently in newly diagnosed CML patients.
. Gleevec is an indication approved by the Mainland Food and Drug Administration for the treatment of the chronic phase, accelerated phase or blast phase of Philadelphia chromosome-positive chronic myelogenous leukemia (+). - For the treatment of chronic, accelerated or blast phase of Philadelphia chromosome-positive chronic myelogenous leukemia (+). For the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumors. Safety and effectiveness information for the following indications mainly comes from foreign research data, and data on the Chinese population are limited: - For the treatment of adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (+). - For the treatment of adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia(R) with R fusion kinase. Imatinib mesylate is the world's first approved tumorigenesis-related signaling inhibitor for chronic myelogenous leukemia and gastrointestinal stromal tumors. Treatment should be initiated initially by a physician experienced in treating chronic myelogenous leukemia. The recommended dose of imatinib mesylate for patients in the blast phase and accelerated phase is /day, and for patients in the chronic phase who have failed interferon treatment, it is /day. Both are taken orally once a day. It is advisable to take the medicine with a meal and drink it once a day. A large glass of water and should be continued for as long as it is effective. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (orally)
. Usage and dosage editing starting dose: for chronic For patients in the blast phase and accelerated phase of myeloid leukemia, the recommended dose of imatinib mesylate is/day. For patients in the chronic phase who have failed interferon therapy, as well as patients with malignant gastrointestinal stromal tumors that cannot be surgically removed or have metastasized, The recommended dose is/day, which should be taken orally once a day. It should be taken with a meal and a large glass of water. As long as it is effective, it should be continued.
. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (taken in divided doses) under the following circumstances: disease progression, treatment at least After 3 months, satisfactory hematological response could not be obtained, and the hematological response that had been achieved disappeared again.
. The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions. .
. Dosage adjustment in case of severe liver toxicity: If the increase in bilirubin exceeds 3 times the upper limit of the normal range or the increase in transaminases exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to the upper limit of the normal range respectively. .or .times or less.
. Dose adjustment in neutropenia or thrombocytopenia: Acceleration or blast phase: If severe neutropenia and thrombocytopenia occur (neutrophils less than ./ and/or platelets less than/), it is recommended The dose is reduced to /day. If the blood cells continue to decrease for weeks, the dose is further reduced to /day. If the blood cells continue to decrease for weeks, it is advisable to stop the drug until neutrophils and platelets are released. The dose is /day when used again.
. -Patients in the chronic phase after interferon treatment failure: it is advisable to stop taking the drug when the neutrophil count is less than ./ and/or the platelet count is less than/, and then resume medication only when the neutrophil count is ./ and the platelet count is ./, the dose is /day , if the neutrophils or platelets decrease to the above values again, the dose should be reduced to /day when the medication is resumed.